Refine by
Obese Articles & Analysis: Older
169 news found
Mouse models for T2DM study is generated by feeding mice a high-fat or high-sugar diet or genetically modifying mice to develop obesity and insulin resistance. These models matter a lot in type 2 diabetes research. ...
IIH can occur in children or adults but is most common in women of childbearing age who are obese. This condition can often cause severe symptoms, including vision problems that can lead to vision loss, frequent hospitalizations, and ongoing health concerns. ...
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
Critics argue that it does not address the underlying problem of obesity and poor lifestyle habits. In addition, the effects of cryolipolysis take time to show and the results are not always long-lasting. ...
For men, it is the second-most diagnosed cancer globally after lung cancer. Advanced age, ethnicity, obesity and family history are known risk factors. In particular, overweight or obese men are at a heightened risk for earlier progression and development of metastatic disease, more adverse effects from treatment and a higher likelihood of fatality. ...
Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 billion people globally will be obese by 2030. In the U.S., nearly $480 billion in direct healthcare costs annually are related to obesity and associated comorbidities. While ...
Dysbiosis of intestinal flora is closely associated with the development of many diseases, such as obesity, diabetes, non-alcoholic fatty liver, inflammatory bowel disease, and tumors. ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive ...
“Peripheral CB1 blockade has the potential to address the significant unmet medical need in DKD as well as other complications of diabetes and obesity.” “We’re excited about the progress of our INV-202 program that represents a novel, orally administered option for treating metabolic conditions,” said François Ravenelle, PhD, Chief Executive ...
If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye disease, kidney disease and nerve damage. World Diabetes Day is held on the 14th of November yearly to mark the birthday of Sir Frederick Banting, the co-founder of insulin. ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like Progressive ...
Meanwhile, soy peptides, consisting of immunomodulatory, antioxidant, and hypocholesterolemic effects, are reported to be beneficial to diabetes, obesity, serum lipids, etc. Pea peptide Alfa Chemistry supplies pea peptides with molecular weights of less than 1 kDa. ...
Lumen’s pipeline is primarily focused on commercial targets, including collaborations with Novo Nordisk (in obesity and cardiometabolic disease) and Kyorin Pharmaceuticals (specific targets not yet disclosed). ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like Progressive ...
Future cerebral therapeutic areas include obesity, Alzheimer's disease, Parkinson's disease, anxiety spectrum disorder, and brain ...
New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by baseline HbA1c, HbA1c variability, and diabetes duration in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) An exploratory ...
ByBayer AG
Inversago believes that peripheral CB1 blockade, either alone or in combination with other therapies, represents an opportunity to address the significant unmet medical need of DKD. As obesity, diabetes and their complications continue to affect more people around the world, the need for new therapies will only continue to grow. ...
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like ...
(NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the winners of its 2017 weight loss contest, which recognizes patients for their successful weight loss with the ReShape Balloon™. ...